Skip to main content

Advertisement

Table 3 Multivariate survival analysis

From: Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy

  Promoter methylation Protein expression
HR 95% CI P value HR 95% CI P value
Variable without interaction term
  Gender 0.83 0.41-1.52 0.44 0.95 0.46-1.76 0.86
  Age 1.10 1.01-1.20 0.002 1.10 1.01-1.12 0.002
  Performance status 0.98 0.92-1.02 0.001 0.98 0.92-1.02 0.001
  Extent of surgery 0.14 0.08-0.22 < 0.001 0.14 0.08-0.24 < 0.001
  MGMT promoter 1.32 1.11-1.56 0.012 1.32 1.11-1.55 0.012
  TMZ therapy 0.29 0.14-0.50 < 0.001 0.29 0.14-0.49 < 0.001
  Promoter methylation 0.62 0.31-1.19 0.15    
  Protein expression     2.11 1.09-3.77 0.02
Variable with interaction terms
  Gender 0.83 0.41-1.55 0.46 1.02 0.50-1.87 0.95
  Age 1.10 1.01-1.20 0.002 1.10 1.01-1.22 0.001
  Performance status 0.98 0.92-1.03 0.002 0.98 0.92-1.02 0.001
  Extent of surgery 0.14 0.08-0.22 < 0.001 0.14 0.08-0.34 < 0.001
  MGMT promoter 1.32 1.11-1.57 0.018 1.32 1.11-1.55 0.012
  TMZ therapy 0.32 0.11-0.83 0.02 0.11 0.03-0.25 < 0.001
  Promoter methylation 0.67 0.59-2.91 0.33    
  Protein expression     1.06 0.45-2.11 0.45
  Promoter methylation × TMZ therapy    0.83    
  Protein expression × TMZ therapy       0.004